[{"id":"b7618037-1369-4803-9a4d-36cc465a98d2","acronym":"","url":"https://clinicaltrials.gov/study/NCT07159906","created_at":"2025-09-13T08:44:39.729Z","updated_at":"2025-09-13T08:44:39.729Z","phase":"Phase 1/2","brief_title":"Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma","source_id_and_acronym":"NCT07159906","lead_sponsor":"First Affiliated Hospital of Zhejiang University","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • prednisone • lisaftoclax (APG-2575) • Synribo (omacetaxine mepesuccinate)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 62","initiation":"Initiation: 09/08/2025","start_date":" 09/08/2025","primary_txt":" Primary completion: 08/01/2027","primary_completion_date":" 08/01/2027","study_txt":" Completion: 08/01/2028","study_completion_date":" 08/01/2028","last_update_posted":"2025-09-08"},{"id":"da510deb-65e1-4eff-9b8a-b593ca5424f3","acronym":"","url":"https://clinicaltrials.gov/study/NCT05147467","created_at":"2024-01-23T19:20:01.388Z","updated_at":"2024-07-02T16:35:22.580Z","phase":"Phase 2","brief_title":"Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL","source_id_and_acronym":"NCT05147467","lead_sponsor":"Ascentage Pharma Group Inc.","biomarkers":" BCL2","pipe":" | ","alterations":" BCL2 expression","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lisaftoclax (APG-2575)"],"overall_status":"Recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 12/28/2021","start_date":" 12/28/2021","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-01-23"},{"id":"bc86132c-0685-40d5-a35a-2bed7aa9e025","acronym":"","url":"https://clinicaltrials.gov/study/NCT04946864","created_at":"2021-07-01T14:54:37.826Z","updated_at":"2024-07-02T16:35:27.876Z","phase":"Phase 1/2","brief_title":"A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer","source_id_and_acronym":"NCT04946864","lead_sponsor":"Ascentage Pharma Group Inc.","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • lisaftoclax (APG-2575)"],"overall_status":"Recruiting","enrollment":" Enrollment 65","initiation":"Initiation: 08/13/2021","start_date":" 08/13/2021","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 10/01/2024","study_completion_date":" 10/01/2024","last_update_posted":"2023-11-28"},{"id":"c9859f5d-e371-4f88-a60c-1b70ab251051","acronym":"","url":"https://clinicaltrials.gov/study/NCT05495035","created_at":"2022-08-10T12:55:24.639Z","updated_at":"2024-07-02T16:35:54.315Z","phase":"Phase 1","brief_title":"Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALL","source_id_and_acronym":"NCT05495035","lead_sponsor":"Institute of Hematology \u0026 Blood Diseases Hospital","biomarkers":" ABL1 • BCR","pipe":" | ","alterations":" BCR-ABL1 T315I • ABL1 T315I • BCR-ABL1 mutation","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCR-ABL1 T315I • ABL1 T315I • BCR-ABL1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dexamethasone • Nailike (olverembatinib) • lisaftoclax (APG-2575)"],"overall_status":"Recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 09/01/2022","start_date":" 09/01/2022","primary_txt":" Primary completion: 08/31/2024","primary_completion_date":" 08/31/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2023-03-02"}]